AdipoRon and Other Adiponectin Receptor Agonists as Potential Candidates in Cancer Treatments

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Neoplastic disorders are a major global health challenge due to high mortality and conventional therapy failures.
• Adipose tissue releases adipokines, including adiponectin, which has demonstrated potential anticancer properties.
• Existing challenges in cancer treatment necessitate innovative therapeutic strategies, such as leveraging the immune system and targeting novel pathways.

Purpose of the Study:

• To review the discovery and anticancer evidence of AdipoRon, an orally active adiponectin receptor agonist.
• To summarize the current state-of-the-art of AdipoRon and other adiponectin receptor agonists in cancer treatment.
• To evaluate the feasibility of using adiponectin receptor agonists as a therapeutic strategy for neoplastic disorders.

Main Methods:

• Literature review of adiponectin, its receptors, and agonists.
• Analysis of preclinical studies on adiponectin receptor agonists, including AdipoRon.
• Inclusion of recent findings in osteosarcoma models to assess anticancer effects.

Main Results:

• Adiponectin receptor agonists, such as AdipoRon, have emerged as potential therapeutic agents.
• Preclinical studies suggest anticancer properties of these agonists.
• Recent findings in osteosarcoma models provide further evidence for their efficacy.

Conclusions:

• AdipoRon and similar compounds represent a promising new avenue for cancer therapy.
• The development of orally active adiponectin receptor agonists offers new therapeutic scenarios.
• Further assessment is required to determine the clinical feasibility of this strategy in treating cancer.